The Use of Natural Volatile Compounds on the Fibrillation Domain of Amyloid Beta (GSNKGAIIGLM)─Towards Promising Agents to Combat Alzheimer’s Disease
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.4c00768 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Zahra Dindar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Biophysics, University of Tehran, P.O. Box 13145-1384 Tehran, Iran. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Peptide Fragments, Volatile Organic Compounds. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: University of Tehran, Mossalanejade's funding foundation.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), which is caused by the accumulation of amyloid-beta, is a major medical concern today. Controlling these aggregates is critical to drug development, but delivering them effectively into the bloodstream poses significant challenges. In this context, aromatherapy has been proposed as an innovative and promising approach for AD disease. The volatile compounds cinnamaldehyde, phenylethyl alcohol, α-asarone, and β-caryophyllene have neuroprotective effects that can be effective in the treatment of neurodegenerative diseases like AD. The amyloid-beta (Aβ) fragment (25-35), which retains the properties of the full-length Aβ is used as a suitable model to evaluate the potential toxicity associated with AD. This study investigated the effects of the four mentioned volatile compounds at four different concentrations on the fibrillation process of the Aβ (25-35) peptide. Structural changes in the peptide have been analyzed using various techniques such as fluorescence probing, far-UV circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). Fluorescence probing results showed that these compounds can effectively prevent the formation of amyloid fibrils by forming chemical bonds with the intermediate species. CD spectroscopy results indicated a decrease in β-sheet content of fibrils and confirmed the effect of pH on structural changes. AFM analysis revealed that volatile compounds effectively prevented the formation of amyloid fibrils at different concentrations and changed the average size of intermediates and oligomeric species. These findings show a promising future for AD patients and emphasize the importance of natural compounds in the treatment and prevention of neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Biophysics, University of Tehran, P.O. Box 13145-1384 Tehran, Iran.
- Peptide Chemistry Research Institute, K. N. Toosi University of Technology, P.O. Box 15875-4416 Tehran, Iran.
- Department of Biology, Science and Research Branch, Islamic Azad University, P.O. Box 1477893855 Tehran, Iran.
ORCID-Profile: Saeed Balalaie, Arefeh Seyedarabi
Förderung
- University of Tehran
- Mossalanejade's funding foundation
Zitieren
APA
Dindar, Z., Anbaraki, A., Hosseini, S. S., Harati, Z., Bahrami, A., Balalaie, S., Ghobeh, M., Mahdavi, M., & Seyedarabi, A. (2025). The Use of Natural Volatile Compounds on the Fibrillation Domain of Amyloid Beta (GSNKGAIIGLM)─Towards Promising Agents to Combat Alzheimer’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00768
Vancouver
Dindar Z, Anbaraki A, Hosseini SS, Harati Z, Bahrami A, Balalaie S, et al. The Use of Natural Volatile Compounds on the Fibrillation Domain of Amyloid Beta (GSNKGAIIGLM)─Towards Promising Agents to Combat Alzheimer’s Disease. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.4c00768
BibTeX
@article{Dindar2025,
author = {Dindar, Zahra and Anbaraki, Afrooz and Hosseini, Seyyed Sina and Harati, Zohreh and Bahrami, Aida and Balalaie, Saeed and Ghobeh, Maryam and Mahdavi, Majid and Seyedarabi, Arefeh},
title = {The Use of Natural Volatile Compounds on the Fibrillation Domain of Amyloid Beta (GSNKGAIIGLM)─Towards Promising Agents to Combat Alzheimer’s Disease},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.4c00768}
}
EUVIMED